• Numerous small, thin-walled cystic lesions distributed throughout both lungs.

Comment

• Can be associated with various interstitial lung diseases like Lymphocytic Interstitial Pneumonia (LIP), Lymphangioleiomyomatosis (LAM), and Langerhans cell histiocytosis (LCH).
• Distribution and specific characteristics on imaging can help differentiate these conditions.

• Lee, Radiology, 2003

• Fluid-filled sacs that form in the kidneys, characterized by a thin wall and containing water-like fluid.

Comment

• Simple renal cysts are very common, and their incidence increases with age; approximately 50% of people over 50 have them.
• They are usually asymptomatic and discovered incidentally during imaging for other reasons.
• Simple cysts are considered benign (Bosniak category I) and typically do not require follow-up unless they become symptomatic or show complex features.

• Pedersen, Br J Radiol, 1993.

• Duration of lithium therapy
• Serum lithium levels
• Episodes of acute lithium intoxication
• Increasing age
• Female gender
• Concurrent use of nephrotoxic medications
• Hypertension
• Diabetes mellitus
• Pre-existing chronic kidney disease (CKD)
• Nephrogenic diabetes insipidus (NDI)

• Lithium enters principal cells of collecting ducts via epithelial sodium channels.
• Impairs intracellular signaling pathways, leading to downregulation of aquaporin-2 (AQP2) and aquaporin-3 water channel proteins.
• Interferes with antidiuretic hormone (ADH) signaling and aquaporin function, disrupting normal renal tubular function, particularly in distal tubules and collecting ducts.
• May contribute to a distal tubular acidification defect, a variant of incomplete distal renal tubular acidosis.

• Chronic tubulointerstitial nephritis (CTIN)
• Tubular atrophy
• Interstitial fibrosis
• Glomerulosclerosis
• Tubular dilation with microcyst formation (1-2 mm, throughout renal cortex and medulla)
• Minimal change nephropathy
• Acute tubular injury

• Nephrogenic diabetes insipidus (NDI)
• Chronic kidney disease (CKD)
• Impaired urinary concentrating ability, leading to polyuria and polydipsia
• Progressive decline in glomerular filtration rate (GFR)
• Potential advancement to stage 3 CKD
• In a smaller proportion of patients, progression to end-stage renal disease (ESRD)

• Magnetic resonance imaging (MRI) typically demonstrates numerous uniform microcysts (1-2 mm) within the renal parenchyma, often distributed equally in the cortex and medulla, appearing hyperintense on T2-weighted sequences.
• Ultrasound may show similar microcysts and punctate echogenic foci.
• CT can reveal microcalcifications within these cysts.

• Chemistry panel: electrolyte abnormalities (hypernatremia, hypokalemia, hypercalcemia), elevated blood urea nitrogen (BUN) and creatinine.
• Urine studies: decreased specific gravity (<1.010) and low urine osmolality (<300 mOsm/kg).
• Serum lithium levels are crucial for assessing toxicity.

• Acute toxicity: correction of electrolyte abnormalities, aggressive fluid repletion, and potentially dialysis.
• Chronic toxicity: addressing polyuria with medications such as amiloride.
• Discontinuation of lithium therapy is often recommended in cases of established CKD.
• Consider alternative mood-stabilizing medications.

• Acute kidney injury associated with lithium toxicity generally has an excellent prognosis.
• NDI may recover over weeks to months after lithium discontinuation, though persistence for years is possible.
• CKD associated with lithium use may not fully resolve but typically does not progress if lithium is discontinued and other nephrotoxic factors are minimized.
• Progression to ESRD can occur, particularly with prolonged lithium exposure (average latency period of ~20 years).
• The rate of progression is often related to the duration of lithium administration.

• The term “lithium” originates from the Greek word “lithos,” meaning “stone,” owing to its discovery in a mineral spring.
• “Nephropathy” is derived from the Greek “nephros” (kidney) and “pathos” (suffering or disease), signifying kidney disease.

• Lithium-induced renal disease
• Lithium-induced chronic renal disease
• Lithium nephrotoxicity
• Lithium-associated renal disease

• The medicinal use of lithium dates back to ancient times, with Galen recommending bathing in alkaline mineral waters, potentially containing lithium, for the treatment of mania around 200 CE.
• In the mid-19th century, lithium was explored for treating uric acid calculi and gout due to the solubility of lithium carbonate in uric acid.
• However, its psychiatric applications were noted in the late 19th century, though toxicity limited widespread acceptance.
• Lithium was briefly used as a substitute in the soft drink 7 Up in the early 20th century but was withdrawn due to toxicity concerns.
• The pivotal report by Australian psychiatrist John Cade in 1949 on the successful use of lithium for bipolar disorder marked a turning point, leading to its broader adoption in psychiatric practice from the 1950s onwards.
• This widespread use spurred intensive studies into lithium’s nephrotoxicity, documenting slowly progressive kidney damage, though rarely leading to end-stage renal disease (ESRD).
• In recent decades, the recognition of lithium nephrotoxicity has led to the adoption of alternative psychiatric agents.

• Lithium’s narrow therapeutic window is a critical factor contributing to the frequency of both acute and chronic toxicity.
• Approximately 30% of patients on lithium experience at least one episode of toxicity.
• The diagnosis of lithium-induced renal disease is often clinical, though renal biopsy can confirm it.
• Imaging findings, particularly on ultrasound, can be characteristic, revealing numerous uniform microcysts and punctate echogenic foci, with CT and MRI showing similar findings.
• Careful monitoring of serum lithium levels and renal function (e.g., serum creatinine and estimated glomerular filtration rate (eGFR)) at regular intervals, typically every six months, is crucial for minimizing risks.
• Guidelines suggest consulting nephrology if eGFR falls below 60 mL/minute/1.73 m².
• The decision to discontinue lithium therapy in patients with chronic kidney disease (CKD) should be a shared one, balancing mental health risks against potential renal progression.

• John Cade: Australian psychiatrist credited with the pivotal 1949 report on the successful use of lithium for treating mania and bipolar disorder, which largely re-introduced lithium into psychiatric practice.

• A Stone’s Tale: The Kidney’s Plea
• From ancient springs, a mineral’s gleam,
• A “stone’s” essence, a hopeful dream.
• John Cade’s insight, a mind set free,
• But kidneys whisper, “Treat us gently.”
• The bipolar tide, a restless sea,
• Lithium’s calm, for you and me.
• Yet tubules toil, a subtle strain,
• As microcysts begin to reign.
• Nephrogenic thirst, a constant call,
• A silent warning, lest we fall.
• For years may pass, a decade’s toll,
• Before the GFR takes its roll.
• So monitor close, with watchful eye,
• Lest damage grow beneath the sky.
• A balancing act, for mental health’s embrace,
• And kidneys’ function, in this fragile race.

• “Lithium has a narrow therapeutic window, and approximately 30% of patients taking lithium experience at least one episode of lithium toxicity.”
• “The most common complication of long-term lithium therapy is nephrogenic diabetes insipidus.”
• “Lithium-induced renal disease can be diagnosed on renal biopsy, however, it is commonly a clinical diagnosis.”
• “The duration of lithium therapy increases the risk of progression to end-stage renal disease (ESRD), however, discontinuation of medication may not necessarily halt the progression to ESRD.”

• Music:
• Nirvana – “Lithium”
• Aloe Blacc – “Lithium”
• Polyphonic Spree – “Lithium”
• LENNY – “Lithium”
• Tom Courtney – “Lithium Poem”
• Janet Kuypers – “Lithium to Calm my Nerves”
• Literature:
• While specific literary works detailing lithium nephropathy are not readily apparent in the search results, the broader theme of mental illness, treatment, and the patient’s internal experience—often depicted in novels and memoirs about bipolar disorder—provides a context for understanding the patient’s journey with lithium.
• Authors like Kay Redfield Jamison (e.g., “An Unquiet Mind”) explore the intricacies of living with bipolar disorder and the role of medication.
• Painting/Sculpture/Photography:
• Direct artistic representations of lithium nephropathy are not found.
• However, broader artistic themes related to internal struggle, the fragility of the body, and the duality of healing and harm could be conceptually linked.
• Abstract art exploring the intricate and often unseen damage within the body, or pieces focusing on the psychological impact of chronic illness, might serve as visual metaphors.

• Lithium enters principal cells of the collecting duct via epithelial sodium channels (ENaC).
• Once intracellularly, lithium inhibits magnesium-dependent G-proteins that activate adenylyl cyclase.
• This leads to a reduction in cyclic adenosine monophosphate (cAMP) production.
• This impairs the vasopressin-induced signaling cascade responsible for regulating aquaporin-2 (AQP-2) water channels.
• Consequently, the downregulation and reduced translocation of AQP-2 to the apical membrane of principal cells impair water reabsorption in the collecting ducts, leading to nephrogenic diabetes insipidus.
• Incorrect Answer B: Lithium does not directly bind to AQP-2 channels.
• Incorrect Answer C: While cell damage occurs, rapid apoptosis is not the primary mechanism for AQP-2 downregulation.
• Incorrect Answer D: Lithium leads to downregulation, not enhancement, of AQP-2 expression.
• Citation: %“Mallick, Kidney Int, 1998“

• While not fully elucidated, studies suggest that mast cells may play a role in lithium-induced nephropathy.
• Mast cells are found in increased numbers in various renal diseases and are associated with interstitial fibrosis and impaired renal function.
• Their presence in the interstitium and connective tissue of the renal pelvis in cases of lithium nephropathy suggests a potential contribution to the inflammatory and fibrotic processes characteristic of this condition.
• Incorrect Answer B: Mast cells are not primarily responsible for lithium excretion.
• Incorrect Answer C: There is no evidence to suggest mast cells have a protective role in clearing lithium compounds.
• Incorrect Answer D: The role of mast cells is primarily implicated in chronic changes, not solely acute toxicity.
• Citation: %“Perazella, Am J Kidney Dis, 2009“

• Chronic lithium nephropathy typically presents with gradual onset of polyuria and polydipsia due to nephrogenic diabetes insipidus.
• It also presents with evidence of chronic kidney disease (CKD), such as elevated serum creatinine and decreased glomerular filtration rate (GFR).
• Acute lithium toxicity, conversely, is characterized by more systemic symptoms including obtundation, volume depletion, and potential cardiovascular collapse.
• Acute toxicity often requires intensive care.
• Incorrect Answer B: Chronic lithium nephropathy does not typically present with acute renal failure, flank pain, or hematuria. Acute toxicity symptoms are more severe than mild thirst and increased urination.
• Incorrect Answer C: While nausea, vomiting, and tremor can occur in both, the primary manifestations and severity differ significantly.
• Incorrect Answer D: Chronic lithium nephropathy does not typically cause rapid GFR decline or hypertension as primary features. Acute toxicity does not lead to persistent polyuria/polydipsia upon cessation.
• Citation: %“Gitlin, Am J Psychiatry, 2002“

• Key risk factors beyond duration include advanced age.
• Cumulative lithium dose is a significant factor.
• A history of acute intoxication episodes increases risk.
• Comorbidities such as hypertension, diabetes mellitus, hyperparathyroidism, and hyperuricemia predispose patients.
• Concurrent use of certain antipsychotics is also a risk factor.
• Incorrect Answer B: Genetic predisposition is not the primary risk factor; environmental and clinical factors are more significant.
• Incorrect Answer C: While pre-existing renal disease increases risk, otherwise healthy individuals can still develop lithium nephropathy.
• Incorrect Answer D: High fluid intake is generally protective against lithium toxicity, and dietary factors are not considered primary risk factors in this context.
• Citation: %“Thomsen, Br J Psychiatry, 2006“

• Characteristic MRI findings include innumerable, small (1-2 mm) microcysts.
• These microcysts are often randomly distributed throughout both the renal cortex and medulla.
• The microcysts are typically T2 hyperintense on MRI.
• This pattern, especially in a patient with a history of lithium use and preserved kidney size, helps differentiate it from conditions like autosomal dominant polycystic kidney disease (ADPKD), which typically presents with larger, variable-sized cysts and often nephromegaly.
• It also helps differentiate from glomerulocystic kidney disease, which primarily affects the cortex.
• Incorrect Answer B: Lithium nephropathy is characterized by microcysts, not large macroscopic cysts similar to ADPKD.
• Incorrect Answer C: Lithium nephropathy typically involves numerous microcysts throughout the kidney, not a single large medullary cyst.
• Incorrect Answer D: Diffuse bilateral renal enlargement and T1 hyperintense cysts are not characteristic of lithium nephropathy; preserved kidney size is more common.
• Citation: %“Neyra, Radiographics, 2012“

• Ultrasound can demonstrate numerous microcysts, sometimes appearing as punctate echogenic foci, typically in normal-sized kidneys.
• CT may show microcalcifications within medullary or cortical microcysts.
• MRI is generally considered superior for visualizing and characterizing the small, diffuse microcysts characteristic of lithium nephropathy, especially when they are subtle.
• Incorrect Answer B: Ultrasound and CT are not as sensitive or specific as MRI for detecting the subtle microcysts of lithium nephropathy, and they do not show large, well-defined cysts.
• Incorrect Answer C: While renal atrophy can occur in chronic disease, CT findings in lithium nephropathy are more specifically related to microcysts and potential calcifications, not just general atrophy.
• Incorrect Answer D: Ultrasound and CT findings are not definitive for diagnosing lithium nephropathy and do not reliably show medullary sponge kidney-like changes as the primary feature. MRI is more sensitive.
• Citation: %“Goh, Eur Radiol, 2005“

• Imaging features supporting lithium nephropathy include the presence of numerous, small (1-2 mm), uniformly distributed microcysts in both the renal cortex and medulla.
• These microcysts are often seen in kidneys of normal size.
• This contrasts with ADPKD, which usually shows enlarged kidneys with larger, variable-sized cysts.
• It also contrasts with medullary cystic kidney disease, which primarily affects the medulla and corticomedullary junction while sparing the cortex.
• Incorrect Answer B: Large, thin-walled cysts and enlarged kidneys are characteristic of ADPKD, not lithium nephropathy.
• Incorrect Answer C: A unilateral large cystic mass with thickened walls and septations suggests a complex cyst or tumor, not lithium nephropathy.
• Incorrect Answer D: Diffuse medullary hyperechogenicity and punctate calcifications can be seen, but minimal cortical involvement is not typical; microcysts are present in both cortex and medulla.
• Citation: %“Perazella, Semin Nephrol, 2011“